Survey Monocef-OCV/CAP/26-27MCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File 1. In your clinical practice, how frequently do you observe Community- Acquired Pneumonia (CAP) in patients with a significant history of heavy smoking (>10 pack-years)? Rarely (Less than 10% of cases) Occasionally (10-30% of cases) Frequently (30-60% of cases) Very Frequently (More than 60% of cases)2. Which clinical challenge do you find most prominent when treating CAP in heavy smokers compared to non-smokers? Delayed symptomatic recovery Higher prevalence of Beta-lactamase-producing pathogens (e.g., H. influenzae, M. catarrhalis) Impaired mucociliary clearance complicating antibiotic penetration All of the above3. Given the high risk of Beta-lactamase-mediated resistance in chronic smokers, how do you rate the necessity of a Beta-lactamase inhibitor (like Clavulanic Acid) in empirical therapy? Essential for most cases Preferred, but not always necessary Only for hospitalized patients Rarely necessary4. How do you evaluate the efficacy of Cefpodoxime Proxetil (an advanced 3rd Gen Cephalosporin) against common CAP pathogens like S. pneumoniae? Excellent; it is a gold standard for oral therapy Good; reliable for mild-to-moderate cases Moderate; requires higher dosing Low; preferred only for pediatric cases5. In smokers with recurrent respiratory infections, what is the primary benefit of adding 125mg of Clavulanic Acid to 200mg of Cefpodoxime? Widens the spectrum to include anaerobic coverage Restores activity against resistant H. influenzae and M. catarrhalis Improves the taste and patient compliance Reduces the duration of therapy by 50%6. When treating CAP in the Indian outpatient setting, how important is "Potent Tissue Penetration" (specifically into bronchial mucosa) for an oral antibiotic? Extremely Important Moderately Important Not a primary consideration Important only in COPD patients7. How would you rate the 200mg/125mg ratio of Cefpodoxime + Clavulanic Acid in terms of balancing clinical efficacy with gastrointestinal (GI) tolerability? Superior; 125mg Clavulanic acid provides optimal inhibition with minimal GI distress Satisfactory; similar to other combinations Needs more clinical data Prefer a lower dose of Clavulanic acid8. Which of the following patient outcomes is most likely to improve in heavy smokers using Cefpodoxime-Clavulanate for CAP? Faster resolution of productive cough Reduced risk of treatment failure/switching to IV therapy Improved eradication of resistant pathogens All of the above9. In terms of patient compliance, how does the twice-daily (BD) dosing of Cefpodoxime + Clavulanic Acid compare to thrice-daily (TDS) alternatives in your experience? Significantly improves adherence Moderately improves adherence No significant difference Depends on the patient's age10. Would you consider Cefpodoxime (200mg) + Clavulanic Acid (125mg) as a first-line oral switch therapy for heavy smokers who have stabilized after initial IV Ceftriaxone? Yes, it is the ideal step-down therapy Only if the culture sensitivity confirms it Rarely; I prefer monotherapy No, I prefer other antibiotic classes (e.g., Macrolides) I have read and agree to the Terms and Conditions .Submit Form